%0 Journal Article
%T Nuevas alternativas en el tratamiento del cancer g¨˘strico avanzado
%A Garrido
%A Marcelo
%A Melgoza
%A Geraldine
%A Galindo
%A H¨¦ctor
%A Madrid
%A Jorge
%A S¨˘nchez
%A C¨¦sar
%A Nervi
%A Bruno
%A Alvarez
%A Manuel
%A Orellana
%A Eric
%J Revista m¨¦dica de Chile
%D 2007
%I Sociedad M¨¦dica de Santiago
%R 10.4067/S0034-98872007001100003
%X background: chemotherapy improves survival in advanced gastric cancer. however the most active combinations have a high level of toxicity that limits their use. aim: to assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (folfox-4 chemotherapy). material and methods: patients with stage ivgastric cancer, according to the american joint committee on cancer or with relapsed disease and functional capacity 0-2 of the south west oncology group, were included. folfox-4 chemotherapy was used as first or second line treatment. the response to treatment and survival were assessed. results: between 2003 and 2006, 29 patients (median age 52.5 years, 69% males) were treated. folfox-4 was given as first line treatment in 65% patients and as second line in 35%. there was a complete response in 4.6%, partial response in 68%, stable disease in 20.6% and progression in 6.8%. toxicity was observed in 51% of patients, that was hematological and non hematological grade 3/4 in 14%. median survival was 12.5 months. conclusions: folfox-4 chemotherapy was active in advanced gastric cancer and had a low level of toxicity
%K antineoplastic combined chemotherapy protocols
%K ¨®rgano platinum compounds
%K stomach neoplasms.
%U http://www.scielo.cl/scielo.php?script=sci_abstract&pid=S0034-98872007001100003&lng=en&nrm=iso&tlng=en